Form 4: OneMedNet Director Receives Equity Compensation

OneMedNet Corp director Sherry Coonse McCraw was granted restricted stock units as compensation for board service in fiscal years 2024 and 2025.

Summary

• Director Sherry Coonse McCraw of OneMedNet Corp [ONMD] was granted a total of 56,342 Restricted Stock Units (RSUs) as compensation for her board service.
• An initial grant of 11,342 RSUs was made on October 1, 2024, for fiscal year 2024 board service, which vested on December 31, 2024.
• A subsequent grant of 45,000 RSUs was reported with a transaction date of November 26, 2025, for fiscal year 2025 board service, which will vest on December 31, 2025, subject to continued service.
• Each RSU represents the contingent right to receive one share of the issuer's common stock and was granted at a price of $0.00.
• All grants were made under the OneMedNet Corporation 2022 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation for a director, which is generally a positive signal of alignment between management and shareholders, contributing to a moderately positive sentiment.

Positives

• The director's receipt of equity compensation aligns her interests with those of shareholders, promoting long-term value creation.
• The grants demonstrate the company's commitment to retaining and incentivizing its board members through equity participation.

Negatives

• No specific negatives are identified in this Form 4 filing, as it primarily reports a routine compensation event.

Risks

• No specific risks are mentioned in this Form 4 filing, which is a transactional report.

Future Outlook

The filing indicates future vesting events for the granted Restricted Stock Units, with 45,000 RSUs scheduled to vest on December 31, 2025, contingent on the director's continued service.

Industry Context

This Form 4 filing reflects a standard practice in the healthcare technology industry, where public companies often use equity compensation, such as Restricted Stock Units, to incentivize and align the interests of their directors and executives with long-term shareholder value. Such compensation structures are common across various sectors to attract and retain experienced board members.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a common practice across publicly traded companies, including those in the healthcare technology sector, aligning with industry standards for executive and board remuneration.
• The grant price of $0.00 for RSUs is typical for compensation awards, as these represent a right to receive shares upon vesting rather than a purchase.

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's interests with shareholders, potentially fostering decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The compensation structure incentivizes the director to remain engaged and contribute to the company's strategic direction.

Next Steps

• The 45,000 RSUs granted for fiscal year 2025 board service are scheduled to vest on December 31, 2025, subject to the reporting person's continued service.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director, which is an expected corporate governance practice. While it signals alignment of interests, it does not provide new fundamental information to warrant a change in investment recommendation. Investors should hold their position and consider broader company performance and market conditions.

Keywords

OneMedNet Corp, ONMD, Form 4, Restricted Stock Units, RSUs, Director Compensation, Equity Incentive Plan, Insider Ownership